10x Genomics (TXG) operating margin

Operating margin · fiscal 2025
-17.2%

10x Genomics (TXG) had an operating margin of -17.2% in fiscal 2025 (the year ended December 31, 2025). That is 14.6 percentage points higher than the -31.9% of fiscal 2024. Figures as of 17 Nov 2026, 20:52 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-17.2%
Change on fiscal 2024
+14.6 pts
Highest on record
-10.7%fiscal 2021
Lowest on record
-178.7%fiscal 2020
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

10x Genomics operating margin, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was -10.7% in fiscal 2021 and the lowest -178.7% in fiscal 2020. The fiscal 2025 figure is higher than in 75% of the 8 earlier fiscal years on record, whose median is -32.2%.

Gross margin was 69.1% in fiscal 2025. Net margin was -6.8% in fiscal 2025.

History · 9 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Gross margin
  • Net margin

10x Genomics operating margin, year by year

10x Genomics (TXG) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedGross marginNet margin
2025-17.2% 14.6 pts up69.1%-6.8%
2024-31.9% 1.2 pts up67.9%-29.9%
2023-33.0% 0.5 pts down66.2%-41.2%
2022-32.5% 21.9 pts down76.7%-32.1%
2021-10.7% 168.1 pts up84.9%-11.9%
2020-178.7% 166.3 pts down80.4%-181.6%
2019-12.4% 63.3 pts up75.2%-12.7%
2018-75.7% 49.9 pts down80.4%-76.9%
2017-25.8%—85.1%-26.4%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

Operating margin at health care companies of similar size

Operating margin of 10x Genomics and comparable companies
CompanyOperating marginFiscal year
Twist Bioscience TWST-36.2%2025
Protagonist Therapeutics PTGX-343.6%2025
Krystal Biotech KRYS41.5%2025
10x Genomics TXG-17.2%2025
HealthEquity HQY24.9%2026
Corcept Therapeutics CORT5.9%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TXG

10x Genomics, figure by figure

10x Genomics (TXG) overview: price, valuation and scorecardAll health care companies by market value

10x Genomics operating margin: questions and answers

What is 10x Genomics's operating margin?

10x Genomics (TXG) had an operating margin of -17.2% in fiscal 2025 (the year ended December 31, 2025). That is 14.6 percentage points higher than the -31.9% of fiscal 2024.

Is 10x Genomics's operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in 75% of the 8 earlier fiscal years on record, whose median is -32.2%.

What are the highest and lowest operating margin figures on record for 10x Genomics?

Across the 9 fiscal years on record (2017–2025), the highest was -10.7% in fiscal 2021 and the lowest -178.7% in fiscal 2020.

What are 10x Genomics's gross and net margins?

Gross margin was 69.1% in fiscal 2025. Net margin was -6.8% in fiscal 2025.

How is 10x Genomics's operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “10x Genomics (TXG) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/TXG/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.